New heart valve implant could offer hope for leaky aortic valve patients
NCT ID NCT04864145
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a new, less invasive heart valve implant (TAVR) with standard medication for people who have severe aortic regurgitation, a condition where the heart's aortic valve doesn't close properly. The trial will enroll 210 participants across multiple centers. The goal is to see if the implant reduces the risk of death, disabling stroke, or heart failure hospitalization compared to medication alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Transcatheter Aortic Valve Implantation (TAVR) device (VitaFlow system)
What this could lead to
If successful, this could provide a less invasive treatment option for people with severe aortic regurgitation who are not candidates for open-heart surgery.
What could go wrong
This is a relatively early study with 210 participants, so results may not apply to everyone. The procedure carries risks like bleeding, need for a permanent pacemaker, or other complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC VALVE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing First Hospital
RECRUITINGNanjing, Jiangsu, 210006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••